Discover Latus’ groundbreaking gene therapy candidates, utilizing high-throughput screened AAV capsids to transform CNS disorder treatments through precision delivery. Latus’ innovative approach aims to target specific tissues, significantly enhancing safety and efficacy for patients.
Total raised: $54M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.05.2024 | Series A | $54M | - |
Mentions in press and media 2
| Date | Title | Description |
| 03.05.2024 | Latus Bio Raises $54M in Series A Financing | Latus Bio, a Philadelphia, PA-based biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), raised $54M in Series A funding. The round was led by 8VC and DCVC Bio. To date, Samsung L... |
| - | Latus Bio | “Discover Latus’ groundbreaking gene therapy candidates, utilizing high-throughput screened AAV capsids to transform CNS disorder treatments through precision delivery. Latus’ innovative approach aims to target specific tissues, significant... |